ALS Drug Development Summit (2nd Annual)
Revolutionizing ALS Models, Novel Biomarkers & Clinical Endpoints to Accelerate Future ALS Approvals Following the approval of Amylyx’s Relyvrio and the upcoming Biogen/Ionis Tofersen FDA decision on the basis of neurofilament light chain as a surrogate endpoint, the ALS drug development landscape is gaining momentum and positivity. With early indications of potential regulatory firsts, booming…